Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 18
MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
David Medina‐Julio, Mariana M. Ramírez-Mejía, Jacqueline Córdova‐Gallardo, et al.
Medical Science Monitor (2024) Vol. 30
Open Access | Times Cited: 12
Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis
Nso Nso, Damla Mergen, Mashaal Ikram, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 6, pp. 102569-102569
Closed Access | Times Cited: 11
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice
Hassam Ali, Muhammad Shahzil, Vishali Moond, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 61-61
Open Access | Times Cited: 9
Review and expert opinion on MAFLD, oxidative stress and multifunctional management
Francesco Angelico, Diana Alcantara‐Payawal, Rafiz Abdul Rani, et al.
Drugs in Context (2024) Vol. 13, pp. 1-11
Open Access | Times Cited: 7
Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
Hideki Mori, Gianluca Svegliati‐Baroni, Marco Marzioni, et al.
Metabolites (2022) Vol. 12, Iss. 7, pp. 647-647
Open Access | Times Cited: 34
The Presence and Severity of NAFLD are Associated With Cognitive Impairment and Hippocampal Damage
Yingwen Miao, Bing Zhang, Xitai Sun, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 12, pp. 3239-3249
Closed Access | Times Cited: 16
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases
Yanyan Wang, Huangru Xu, Xiqiao Zhou, et al.
Medical Review (2024) Vol. 4, Iss. 4, pp. 262-283
Open Access | Times Cited: 6
Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease
Seyed Ahmad Hosseini, Meysam Alipour, Sara Sarvandian, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern!
Akash Batta, Juniali Hatwal
World Journal of Cardiology (2024) Vol. 16, Iss. 7, pp. 380-384
Open Access | Times Cited: 5
Development and validation of a metabolic syndrome and its components to predict the efficacy of neoadjuvant chemotherapy in breast cancer: An observational, single-center, cohort study
Xiangdong Zhao, Chengfang Jia, Shuaichong Ji, et al.
Medicine (2025) Vol. 104, Iss. 2, pp. e41221-e41221
Open Access
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access
Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia
杨 包
Advances in Clinical Medicine (2025) Vol. 15, Iss. 02, pp. 1996-2004
Closed Access
Consumption of Tree Nuts as Snacks Stimulates Changes in Plasma Fatty Acid Profiles and Adipose Tissue Gene Expression in Young Adults at Risk for Metabolic Syndrome
Annaliese Widmer, Kate Lillegard, Katharine M Wood, et al.
Clinical Nutrition (2025) Vol. 48, pp. 25-34
Open Access
Expression profile and N6-methyadenosine modification of circular RNA analysis in MAFLD
Mengyao Zheng, Dongyun Cun, Haiyu He, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
Eda Kaya, Yusuf Yılmaz
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 25
The role of complement in nonalcoholic fatty liver disease
Zhenya Guo, Xiude Fan, Jianni Yao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis
Yixuan Li, Yanyu Zhou, Liya Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 24
Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions
Cunsi Ye, Weidong Han, Shaomin Lin, et al.
Molecules (2023) Vol. 28, Iss. 4, pp. 1874-1874
Open Access | Times Cited: 12
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease
Qiang Ren, Ya Chen, Zongtao Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6082-6104
Closed Access | Times Cited: 12
Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Salvatore Pezzino, Tonia Luca, M. Castorina, et al.
Life (2024) Vol. 14, Iss. 1, pp. 93-93
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top